Ascentage Pharma Group International (NASDAQ:AAPG) Shares Up 20.3% – Here’s What Happened

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) traded up 20.3% during trading on Wednesday . The stock traded as high as $23.00 and last traded at $22.9850. 202 shares traded hands during mid-day trading, a decline of 94% from the average session volume of 3,402 shares. The stock had previously closed at $19.11.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Oppenheimer assumed coverage on shares of Ascentage Pharma Group International in a report on Thursday, December 4th. They set an “outperform” rating and a $45.00 price target for the company. Rodman & Renshaw started coverage on shares of Ascentage Pharma Group International in a research report on Tuesday, January 13th. They set a “buy” rating and a $48.00 price objective for the company. BTIG Research began coverage on Ascentage Pharma Group International in a research note on Thursday, March 12th. They set a “buy” rating and a $48.00 target price for the company. Finally, Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, December 15th. Two analysts have rated the stock with a Strong Buy rating and five have assigned a Buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $48.00.

Ascentage Pharma Group International Price Performance

The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54. The company has a 50 day simple moving average of $24.33 and a 200 day simple moving average of $30.11.

Hedge Funds Weigh In On Ascentage Pharma Group International

A number of institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Ascentage Pharma Group International in the third quarter valued at approximately $96,000. ABC Arbitrage SA bought a new stake in shares of Ascentage Pharma Group International during the third quarter worth $204,000. Citadel Advisors LLC acquired a new position in shares of Ascentage Pharma Group International during the third quarter worth $383,000. Hsbc Holdings PLC bought a new position in shares of Ascentage Pharma Group International in the 2nd quarter valued at $391,000. Finally, Tema Etfs LLC bought a new position in shares of Ascentage Pharma Group International in the 2nd quarter valued at $610,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.